Sector News

Activists want Spectrum to dump its CEO and find a buyer

May 13, 2015
Life sciences
Hedge fund Armistice Capital has taken a 5.4% stake in Spectrum Pharmaceuticals, agitating for sweeping changes in how the biotech does business and demanding it find a buyer on the quick.
 
Armistice, led by founder Steve Boyd, contends that Spectrum is bloated, poorly managed and in desperate need of change after years of broken promises. In a letter to Spectrum’s board, Boyd disclosed his firm’s 3.6 million-share stake and asked the company to dump its “money-losing” R&D activities and recruit a “top-tier investment bank” to find a buyer. In the meantime, CEO Rajesh Shrotriya should either resign or “adjust (his) compensation to better align with the interests of shareholders,” Boyd wrote.
 
The last straw, according to Armistice, came in February when Spectrum’s shares plunged after a federal court invalidated some patents tied to the cancer drug Fusilev, clearing the way of Novartis’ Sandoz to launch a generic. That very night, with half of Spectrum’s revenue suddenly imperiled, the company awarded $2 million in cash bonuses to its top four execs, according to Boyd, typifying the “dysfunctional culture” that has marred shareholder value.
 
To groom Spectrum for an acquisition, Boyd proposes “a combination of reducing management compensation and employee headcount, significantly curtailing research and development, eliminating excessive corporate offices, and focusing on in-licensing and co-promotion opportunities.” He mentions the research-averse Valeant Pharmaceuticals as a potential model, recommending Spectrum spin out some of its riskier pipeline assets into a standalone biotech company.
 
In making his case, Boyd lays out a long list of failings and misguided projections from Shrotriya and Spectrum’s management, including promises that Fusilev was safe through 2022 and that the bladder cancer treatment apaziquone would be submitted to the FDA in 2013. It remains unfiled.
 
“I will be the first to acknowledge that the business of forecasting is a thankless profession,” Boyd wrote. “Nonetheless, the disconnect between your statements and reality have created distrust in the investment community, employee turnover, shareholder lawsuit expense and an SEC investigation that is on-going.”
 
Spectrum’s shares rose more than 7% before the market opened on Tuesday.
 
By Damian Garde
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).